In the News: US Lawmakers Seek Increased Scrutiny of US Clinical Drug Trials in China; China Eases Foreign Investment Rules; and Wealth Connect Scheme Expanded

August 28, 2024 | BY

Clarence Lee, Brian Chan &Krista Lee

U.S. lawmakers call on the government to scrutinize drugmakers' clinical trials in China; China removes restrictions for foreign investments in the manufacturing and services industries; and Cross-Boundary Wealth Connect gains 10 new additional securities firms for increased offshore investment opportunities.

Promulgated: 2024-08-20

Credit: Vladimir/Adobe Stock

|

US Drugmakers' Clinical Trials in China Under Scrutiny

A bipartisan group of U.S. lawmakers sent a letter to the U.S. Food and Drug Administration last week, asking that it increase scrutiny of U.S. clinical trials conducted in China, according to Reuters.

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]